{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Appendix 6 Laboratory Evaluations', 'Hematology', 'Hemoglobin, platelet count, white blood cell (WBC) count with WBC', 'differential', 'Clinical Chemistry', 'Creatinine, creatinine clearance, blood urea nitrogen (BUN), glucose,', 'glycosylated hemoglobin [HbA1c], alanine aminotransferase (ALT),', 'aspartate aminotransferase (AST), total bilirubin, gamma-glutamyl', 'transferase (GGT), C-reactive protein (CRP), alkaline phosphatase (ALP),', 'lactate dehydrogenase (LDH), uric acid, albumin, potassium, sodium,', 'calcium, lipid panel (total cholesterol, high density lipoprotein [HDL], low', 'density lipoprotein [LDL], and triglycerides), international normalized ratio', '(INR) and activated partial thromboplastin time (aPTT).', 'Total IgG at Screening only\u00b9', 'Urinalysis', 'Color, clarity/appearance, specific gravity, pH, protein, glucose, ketones,', 'blood, bilirubin, urobilinogen, nitrite, leukocyte esterase, and microscopic', 'examination including red blood cell (RBC) count, WBC, cast crystals,', 'bacteria.', 'Serology', 'Human immunodeficiency virus (HIV) antibodies (1 and 2), Hepatitis B', 'surface antigen (HBsAg), antibodies to the surface and core antigens of the', 'hepatitis B virus (anti-HBs and anti-HBc), hepatitis C virus antibody', '(HCV-Ab)', 'Other', 'Serum and urine human chorionic gonadotrophin (B-HCG),', 'Follicle-stimulating hormone (FSH) test', 'Pharmacokinetics (PK)', 'Concentration levels of ARGX-113', 'AChR-/MuSK-antibody', 'AChR-antibody (binding) levels and anti-muscle-specific kinase (MuSK)', 'serotype', 'antibodies (in all patients; at Screening only)2', 'Pharmacodynamic (PD)', 'Total IgG and subtypes (IgG1, IgG2, IgG3, and IgG4), and AChR-Ab', 'markers', '(binding) levels in AChR-Ab seropositive patients only and anti-MuSK', 'antibodies in MuSK-Ab seropositive patients only', 'Anti-drug antibodies', 'Levels of anti-ARGX-113 binding and neutralizing antibodies (if applicable)', '(ADA)', 'Note: All blood and urine samples will be collected locally (pre-dose on dosing days) and analyzed centrally.', '1 For eligibility purpose, total IgG will be measured (as part of clinical lab) centrally at Screening. At all other', 'timepoints, total IgG will be analyzed, together with the other PD parameters, by a specialty lab.', '2 In case the AChR-Ab result is not available in time (i.e. within the 2 weeks screening window), the screening', 'window can be enlarged on an ad-hoc base with maximum 5 calendar days.', 'argenx BVBA', 'Confidential', 'Page 107 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'CCI', 'argenx BVBA', 'Confidential', 'Page 108 of 110']\n\n###\n\n", "completion": "END"}